Historical cohort analysis of treatment patterns for patients with type 2 diabetes initiating metformin monotherapy

References

• Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89
   PubMed Web of Science ®Google Scholar
• Rowley WR, Bezold C. Creating public awareness: state 2025 diabetes forecasts. Popul Health Manag 2012;15:194-200
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care 2013;36:1033-46
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes – 2015: summary of revisions. Diabetes Care 2015;38(Suppl):S4
   Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• Boussageon R, Supper I, Bejan-Angoulvant T, et al. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PLoS Med 2012;9:e1001204
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-79
   PubMed Web of Science ®Google Scholar
• Nichols GA, Conner C, Brown JB. Initial nonadherence, primary failure and therapeutic success of metformin monotherapy in clinical practice. Curr Med Res Opin 2010;26:2127-35
   PubMed Web of Science ®Google Scholar
• Stolar MW, Hoogwerf BJ, Gorshow SM, et al. Managing type 2 diabetes: going beyond glycemic control. J Manag Care Pharm 2008;14(5 Suppl B):s2-19
   PubMed Web of Science ®Google Scholar
• Dichtwald S, Weinbroum AA, Sorkine P, et al. Metformin-associated lactic acidosis following acute kidney injury. Efficacious treatment with continuous renal replacement therapy. Diabet Med 2012;29:245-50
   PubMed Web of Science ®Google Scholar
• Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 2004;27:1535-40
   PubMed Web of Science ®Google Scholar
• Brown JB, Conner C, Nichols GA. Secondary failure of metformin monotherapy in clinical practice. Diabetes Care 2010;33:501-6
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of Medical Care in Diabetes – 2014. Diabetes Care 2014;37:(Suppl):S15
   Google Scholar
• Xu Y, Viswanathan HN, Ward MA, et al. Patterns of osteoporosis treatment change and treatment discontinuation among commercial and Medicare Advantage Prescription Drug members in a national health plan. J Eval Clin Pract 2013;19:50-9
   PubMed Web of Science ®Google Scholar
• Chang H-Y, Weiner JP, Richards TM, et al. Predicting costs with diabetes complications severity index in claims data. Am J Manag Care 2012;18:213-19
   PubMed Web of Science ®Google Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19
   PubMed Web of Science ®Google Scholar
• Klabunde CN, Potosky AL, Legler JM, et al. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000;53:1258-67
   PubMed Web of Science ®Google Scholar
• Rubin RR. Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. Am J Med 2005;118(Suppl 5A):27-34S
   PubMed Web of Science ®Google Scholar
• Hertz RP, Unger AN, Lustik MB. Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer-sponsored health insurance. Clin Therapeut 2005;27:1064-73
   PubMed Web of Science ®Google Scholar
• Gregoire JP, Sirois C, Blanc G, et al. Persistence patterns with oral antidiabetes drug treatment in newly treated patients – a population-based study. Value Health 2010;13:820-8
   PubMed Web of Science ®Google Scholar
• Florez H, Luo J, Castillo-Florez S, et al. Impact of metformin-induced gastrointestinal symptoms on quality of life and adherence in patients with type 2 diabetes. Postgrad Med 2010;122:112-20
   PubMed Web of Science ®Google Scholar
• Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12
   PubMed Web of Science ®Google Scholar
• Walker EA, Molitch M, Kramer MK, et al. Adherence to preventive medications: predictors and outcomes in the Diabetes Prevention Program. Diabetes Care 2006;29:1997-2002
   PubMed Web of Science ®Google Scholar
• Knol MJ, Heerdink ER, Egberts ACG, et al. Depressive symptoms in subjects with diagnosed and undiagnosed type 2 diabetes. Psychosom Med 2007;69:300-05
   PubMed Web of Science ®Google Scholar
• Golden SH, Lazo M, Carnethon M, et al. Examining a bidirectional association between depressive symptoms and diabetes. JAMA 2008;299:2751-9
   PubMed Web of Science ®Google Scholar
• Kirkman MS, Briscoe VJ, Clark N, et al. Diabetes in older adults. Diabetes Care 2012;35:2650-64
   PubMed Web of Science ®Google Scholar
• de Rekeneire N, Rooks RN, Simonsick EM, et al. Racial differences in glycemic control in a well-functioning older diabetic population: findings from the Health, Aging and Body Composition Study. Diabetes Care 2003;26:1986-92
   PubMed Web of Science ®Google Scholar
• Heisler M, Faul JD, Hayward RA, et al. Mechanisms for racial and ethnic disparities in glycemic control in middle-aged and older Americans in the health and retirement study. Arch Intern Med 2007;167:1853-60
   PubMed Web of Science ®Google Scholar
• Shenolikar RA, Balkrishnan R, Camacho FT, et al. Race and medication adherence in Medicaid enrollees with type-2 diabetes. J Natl Med Assoc 2006;98:1071-7
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus? Drugs 2003;63:933-51
   PubMed Web of Science ®Google Scholar
• Garber AJ. Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting. Am J Manag Care 2010;16(7 Suppl):S187-94
   Google Scholar
• Fu H, Curtis BH, Xie W, et al. Frequency and causes of hospitalization in older compared to younger adults with type 2 diabetes in the United States: a retrospective, claims-based analysis. J Diabetes Complications 2014;28:477-81
   PubMed Web of Science ®Google Scholar
• Lustman PJ, Penckofer SM, Clouse RE. Recent advances in understanding depression in adults with diabetes. Curr Diabetes Rep 2007;7:114-22
   PubMedGoogle Scholar
• Gonzalez JS, Fisher L, Polonsky WH. Depression in diabetes: have we been missing something important? Diabetes Care 2011;34:236-9
   PubMed Web of Science ®Google Scholar
• Von Korff M, Katon W, Lin EH, et al. Work disability among individuals with diabetes. Diabetes Care 2005;28:1326-32
   PubMed Web of Science ®Google Scholar
• Shrestha SS, Zhang P, Li R, et al. Medical expenditures associated with major depressive disorder among privately insured working-age adults with diagnosed diabetes in the United States, 2008. Diabetes Res Clin Pract 2013;100:102-10
   PubMed Web of Science ®Google Scholar
• Koopmans B, Pouwer F, de Bie RA, et al. Depressive symptoms are associated with physical inactivity in patients with type 2 diabetes. The DIAZOB Primary Care Diabetes study. Family Practice 2009;26:171-3
   PubMed Web of Science ®Google Scholar
• Arday SL, Arday DR, Monroe S, et al. HCFA's racial and ethnic data: current accuracy and recent improvements. Health Care Financ Rev 2000;21:107-16
   PubMed Web of Science ®Google Scholar
• Palacio AM, Tamariz LJ, Uribe C, et al. Can claims-based data be used to recruit black and Hispanic subjects into clinical trials? Health Services Res 2012;47:770-82
   PubMed Web of Science ®Google Scholar